OxyContin maker Purdue Pharma to plead guilty to 3 criminal charges

WASHINGTON —  Drugmaker Purdue Pharma, the company behind the powerful prescription painkiller OxyContin, which experts say helped touch off an opioid epidemic, will plead guilty to federal criminal charges as part of a settlement of more than $8 billion, the Justice Department announced Wednesday.

The deal does not release any of the company’s executives or owners — members of the wealthy Sackler family — from criminal liability, and a criminal investigation is ongoing. Family members said they acted “ethically and lawfully,” but some state attorneys general said the agreement fails to hold the Sacklers accountable.

The company will plead guilty to three counts, including conspiracy to defraud the United States and violating federal anti-kickback laws, the officials said, and the agreement will be detailed in a bankruptcy court filing in federal court.

The Sacklers will lose all control over their company, a move already in the works, and Purdue will become a public benefit company, meaning it will be governed by a trust that has to balance the trust’s interests against those of the American people and public health, officials said.

The settlement is the highest-profile display yet of the federal government seeking to hold a major drugmaker responsible for an opioid addiction and overdose crisis linked to more than 470,000 deaths in the country since 2000.

It comes less than two weeks before a presidential election in which the opioid epidemic has taken a political back seat to the COVID-19 pandemic and other issues, and gives President Trump’s administration an example of action on the addiction crisis, which he promised early on in his term.

Ed Bisch, who lost his 18-year-old son to an overdose nearly 20 years ago, said he wants to see people associated with Purdue prosecuted and was glad the Sackler family wasn’t granted immunity.

He blames the company and the Sacklers for thousands of deaths. “If it was sold for severe pain only from the beginning, none of this would have happened,” said Bisch, who lives in Westampton, N.J. “But they got greedy.”

Brooke Feldman, a 39-year-old Philadelphia resident who is in recovery from opioid use disorder and is a social worker, said she is glad to see Purdue admit wrongdoing. She said the company had acted for years as “a drug cartel.”

Democratic attorneys general criticized the agreement as a “mere mirage” of justice for victims.

“The federal government had the power here to put the Sacklers in jail, and they didn’t,” Connecticut Atty. Gen. William Tong said in a statement. “Instead, they took fines and penalties that Purdue likely will never fully pay.”

But members of the Sackler family, once listed as one of the nation’s wealthiest by Forbes magazine, said they had acted “ethically and lawfully” and that company documents required to be made public under the settlement will show that.

“Purdue deeply regrets and accepts responsibility for the misconduct detailed by the Department of Justice in the agreed statement of facts,” Steve Miller, who became chairman of the company’s board in 2018, said in a statement. No members of the Sackler family remain on that board, though they still own the company.

Family members, in a statement, expressed “deep compassion for people who suffer from opioid addiction and abuse and hope the proposal will be implemented as swiftly as possible to help address their critical needs.”

As part of the resolution, Purdue is admitting that it impeded the Drug Enforcement Administration by falsely representing that it had maintained an effective program to avoid drug diversion and by reporting misleading information to the agency to boost the company’s manufacturing quotas, the officials said.

Purdue is also admitting to violating federal anti-kickback laws by paying doctors, through a speaking program, to induce them to write more prescriptions for the company’s opioids and using electronic health records software to influence the prescription of pain medication, according to the officials.

Purdue will make a direct payment to the government of $225 million, which is part of a larger $2-billion criminal forfeiture. In addition to that forfeiture, Purdue also faces a $3.54-billion criminal fine, though that money probably will not be fully collected because it will be taken through a bankruptcy, which includes a large number of other creditors, including thousands of state and local governments. Purdue will also agree to $2.8 billion in damages to resolve its civil liability.

Part of the money from the settlement would go to aid in medication-assisted treatment and other drug programs to combat the opioid epidemic. That part of the arrangement echoes the plan that the company is pushing in bankruptcy court and that about half the states oppose.

As part of the plea deal, the company admits it violated federal law and “knowingly and intentionally conspired and agreed with others to aid and abet” the dispensing of medication from doctors “without a legitimate medical purpose and outside the usual course of professional practice,” according to the plea agreement.

Although some state attorneys general opposed the prospect of Purdue becoming a public benefit company, the lead lawyers representing 2,800 local governments in lawsuits against Purdue and other drugmakers, distributors and pharmacies put out a statement supporting the principle but saying more work needs to be done.

The Sackler family has already pledged to hand over the company plus at least $3 billion to resolve thousands of suits against the Stamford, Conn.-based drugmaker. The company declared bankruptcy as a way to work out that plan, which could be worth $10 billion to $12 billion over time. In their statement, family members said that is “more than double all Purdue profits the Sackler family retained since the introduction of OxyContin.”

“Both the company and the shareholders are paying a very steep price for what occurred here,” Deputy U.S. Atty. Gen. Jeffrey Rosen said Wednesday.

Although there are conflicting views of whether it’s enough, it’s clear the Sacklers’ reputation has taken a hit.

Until recently, the Sackler name was on museum galleries and educational programs around the world because of gifts from family members. But under pressure from activists, institutions such as the Louvre in Paris and Tufts University in Massachusetts have dissociated themselves from the family in the last few years.